SyncThink and Pico extend partnership

SyncThink, a neurotechnology company and developer of the award-winning EYE-SYNC technology, has expanded its partnership with Pico Interactive, a technology company that develops VR and enterprise solutions, and the integration of its platform onto the Pico Neo 3 Pro Eye headset. 

With the added availability of the 3 Pro Eye headset, the FDA Cleared EYE-SYNC technology is now accessible on three innovative XR devices, with a fourth in development and additional device integrations to be announced. 

Scott Anderson, SyncThink CCO, said: “We are excited to continue our work with Pico on the 3 Pro Eye to continue to provide clinicians with the latest technological advancements in Virtual Reality, whilesimultaneously delivering a best-in-class patient experience.” 

Mika Cavanaugh, US account director for Pico Interactive, added: “We value our growing relationship with the SyncThink team and are pleased by their commitment to using the 3 Pro Eye to better serve their product mission. It is exciting to see Pico’s unique XR devices enable their market leading software and analytics tools to become more accessible to patient care sites everywhere.”

The Neo 3 Pro Eye enables EYE-SYNC to leverage a fully integrated headset that allows patient assessments to begin within ten seconds of power-up. With built-in Tobii eye tracking capabilities operating at 90Hz, clinicians can capture more significant and robust data to support clinical decisions. Additional features such as surround sound spatial audio automate the test procedures and patient instructions, saving valuable time in the process. SyncThink will begin deploying Neo 3 headsets this month, including offering upgrade pathways for existing customers.

SyncThink and the EYE-SYNC technology received its second FDA Clearance in 2021 as an Aid to Concussion Diagnosis, or mild Traumatic Brain Injury (mTBI) Diagnosis. It combines proprietary software and data analytics with high performance eye tracking sensors to measure and quantify eye movement biomarkers reflective of impairment or disease. It is currently used by healthcare providers in hospitals and rehabilitation centres, sports, military, and in CNS drug development around the world.